The Fast Money traders take a look at today's biggest market movers.» Read More
The Food and Drug Administration late this morning put out a news release with the heading, "FDA Receives New data on Risks of Anemia Drugs." This is more bad news for an additional population of cancer patients and, of course, Amgen and, to a lesser extent, Johnson and Johnson.
Maybe it's because of the Iowa caucus' taking place Wednesday night. Maybe it's because at the start of a new year, it's a good time to make predictions. Or maybe it's because the auto show season is about to kick off with the automakers putting out their visions for the future. Whatever the reason, I think today is the day to ask YOU which automaker has the most to show, prove, gain, lose in 2008?
The credit crunch and housing crisis led to some high-profile firings, most notably Merrill Lynch's Stan O'Neal and Citigroup's Chuck Prince. Still, while they lost their jobs, these executives didn't lose their shirts.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
With Detroit and much of the auto industry shut down this week and gearing up for the Detroit Auto Show next month, I thought it would be a good time to take a few minutes and share my Christmas wishes for the auto world. I hope Santa brings you everything you want.
Yes, I'd rather be blogging about another topic by now, but I hope this will be the last entry -- at least for awhile -- on the Avastin vs. Lucentis story. You see, last Friday I got repeatedly voice-mailed and e-mailed by Christine Castro, the new head of corporate communications/media relations at Genentech...
MBIA CEO Gary Dunton "has the touch of a great novelist" when it comes to the company's financial reports, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Thanks to quantitative models, this fund has eliminated human emotion from its investment decisions.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.
Occasionally, when I state my opinion about a particular car or automaker, I get swamped with e-mails from people who think I'm an idiot. Yesterday was one of those days: I was talking about the new Corvette ZR1...
Network equipment maker Cisco Systems said Chief Development Officer Charles Giancarlo, widely seen as a leading candidate for future CEO, is leaving the company.
Genentech today has essentially backed down from a proposed crackdown on doctors' use of the cancer drug Avastin instead of the way more expensive Lucentis. The drugs are used to treat age-related macular degeneration (AMD, for short), which is the leading cause of blindness in adults.
As we close out this year, I know some of you are asking, "Hey Toyota Phil (a nickname a friend gave me after accusing me of giving the Japanese automaker too much praise) what do you think will happen in the auto industry next year?" Well, since you asked, and I know some of you haven't asked, here are my prognostications for 2008.
This stodgy old company has a huge growth story.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.
Bear Stearns's board is talking about a successor for Chief Executive Jimmy Cayne, CNBC has learned.
1st paragraph of story should go here
Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.
Sprint Nextel on Tuesday named former Embarq Corp Chief Executive Dan Hesse as its president and CEO, effective immediately.
Merry Christmas! The ECB's decision to inject half a trillion (trillion!) into the global marketplace (technically, they are providing what is essentially unlimited loans at a fixed fate for the next couple weeks) is definitely giving equities a shot in the arm this morning. This should put some pressure on bonds, lower LIBOR rates, and maybe prop up the dollar a bit.